Granulocyte aggregometry: a sensitive technique for the detection of C5a and complement activation.
We have previously shown that complement (C) activated plasma causes granulocyte (PMN) aggregation in vitro and that C5a is responsible. The C-induced aggregation of PMNs treated with cytochalasin-B (CB) is markedly enhanced and irreversible, and the magnitude of the response is proportional to the log (concentration of activated plasma), allowing use of this technique to detect C5a and hence C-activation. To compare the sensitivity of granulocyte aggregometry to that of more standard methods of detecting C-activation, we produced graded C-activation in vitro by treating fresh serum with varying amounts of zymosan. Aggregometry was the most sensitive index of C-activation, detecting C-activation, produced by 0.02 mg zymosan/ml of serum--1/10 that required to produce C-activation detectable by C3 immunoelectrophoresis (the next most sensitive technique). Granulocyte aggregometry may also be used to detect in vivo C-activation. We have found aggregating activity in plasmas from patients with systemic lupus erythematosus, immune vasculitis, transfusion reactions, and other conditions associated with in vivo C-activation, but not in the plasmas of normal subjects.
D002449:Cell Aggregation / Q000187:drug effects; D002634:Chemotaxis, Leukocyte; D003167:Complement Activation; D003176:Complement C3; D003182:Complement C5; D003170:Complement Pathway, Alternative; D003571:Cytochalasin B / Q000494:pharmacology; D006098:Granulocytes / Q000276:immunology*; D006801:Humans; D007122:Immunoelectrophoresis; D007158:Immunologic Techniques; D015054:Zymosan / Q000494:pharmacology
D003176:Complement C3; D003182:Complement C5; D003571:Cytochalasin B; D015054:Zymosan